Group 1 - GSK has entered the weight loss market by acquiring 35Pharma and introducing the HS235 drug for fat-selective weight loss and muscle mass preservation [1] - GSK's shares have increased by 38% over the past year, reflecting positive market sentiment since Jim Cramer recommended the stock in March 2025 [1] - The company reported fourth-quarter earnings of 8.6 billion pounds in revenue and 25.5 pence in earnings per share, surpassing analyst expectations [1] Group 2 - Following the third-quarter earnings report, GSK raised its 2025 revenue growth estimates from 3%-5% to 6%-7%, with reported revenue of 8.6 billion pounds and earnings per share of 55 pence [1] - Jim Cramer praised GSK, highlighting its low price-to-earnings ratio and 4% yield, indicating it as a strong investment opportunity [1]

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - Jichuan Pharmaceutical has secured exclusive commercialization rights for the drug Bimekizumab (brand name: Zeli Mei) in mainland China, excluding Hong Kong, Macau, and Taiwan, with a total payment not exceeding RMB 190 million (including tax) [3][13] - Bimekizumab is the first approved treatment for eczema in children aged 2 and above, acting as an aromatic hydrocarbon receptor (AhR) modulator to suppress inflammation and repair skin barriers [3][13] - The product is expected to be approved for market launch in November 2024 and currently is not included in the National Basic Medical Insurance Drug List, indicating it is in the early stages of market expansion [3][13] Summary by Sections Industry Viewpoints - The report emphasizes the continuous improvement of global competitiveness among Chinese innovative pharmaceutical companies, suggesting a focus on potential treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders [4] - It also highlights emerging technology platforms like small nucleic acid drugs and CAR-T therapies, recommending companies such as Baiji Shenzhou and Dongcheng Pharmaceutical for investment [4] Industry News - Jichuan Pharmaceutical's acquisition of Bimekizumab is noted as a significant development in the biopharmaceutical sector, providing a new treatment option for eczema [7][13] - GSK's acquisition of 35Pharma for $950 million to gain access to a new pulmonary arterial hypertension drug is also highlighted, showcasing ongoing consolidation in the industry [14] - GSK's submission of a new hepatitis B drug, Bepirovirsen, for market approval in Japan is mentioned, indicating advancements in chronic hepatitis treatment [16][17] - The approval of a new JAK/ROCK inhibitor by Zhengda Tianqing for treating primary myelofibrosis is noted, reflecting innovation in hematological therapies [18] Market Performance - The pharmaceutical sector saw a 0.50% increase last week, while the Shanghai and Shenzhen 300 Index rose by 1.08%, ranking 21st among 28 industries [8][20] - The Hong Kong pharmaceutical sector experienced a decline of 6.07%, with the Hang Seng Index down by 1.93%, ranking 11th among 11 industries [31]

Group 1 - Xiansheng Pharmaceutical expects a net profit increase of 80.1% to 93.9% for the fiscal year 2025, with projected revenue of approximately RMB 7.7 billion to 7.8 billion, reflecting a year-on-year growth of about 16.0% to 17.6% [1] - The growth in revenue and profit is attributed to increased income from innovative drugs, licensing income, and net gains from the fair value of the investment portfolio [1] Group 2 - GSK has announced the acquisition of 35Pharma for $950 million in cash, gaining access to an early-stage hypertension drug asset, HS235, which has completed Phase I clinical trials [2] - This acquisition marks GSK's expansion into the cardiovascular drug sector, addressing financial pressures from expiring patents on key HIV drugs [2] Group 3 - BioMarin has decided to withdraw its gene therapy Roctavian for hemophilia A from the market after failing to find a buyer, with sales of only $26 million in 2024 and a slight increase to $36 million in 2025 [3] - The withdrawal highlights challenges in the high-value rare disease drug market, including competition and reimbursement difficulties [3] Group 4 - Sanofi's new drug application for SSGJ-611, a humanized monoclonal antibody for atopic dermatitis, has been accepted by the National Medical Products Administration, with promising results from Phase III clinical trials [4] - The prevalence of atopic dermatitis has been increasing globally, with a reported adult prevalence rate of 6.1% in China, which may boost investor confidence [4] Group 5 - Novo Nordisk announced that its weight loss drug Wegovy will be sold at half price in the U.S. starting January 1, 2027, with a unified wholesale price of $675 for its GLP-1 product line [5] - The price reduction aims to lower patient out-of-pocket costs and make the drug more accessible, while also addressing increasing market competition [5]

Company Overview - 35Pharma is a Canada-based, private, clinical-stage biopharmaceutical company focused on developing novel protein-based therapeutics [1][9] - The company's lead candidate, HS235, is designed for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) [1][9] Acquisition Details - GSK plc will acquire 100% of the equity of 35Pharma for $950 million, payable in cash at closing [5] - The acquisition is subject to customary conditions, including regulatory agency clearances in the US and Canada [5] Product Information - HS235 is a potential best-in-class investigational medicine that has completed phase I clinical trials and is set to begin studies in PAH and PH-HFpEF [1][6] - The drug targets the activin receptor signalling pathway, which is clinically validated for PAH treatment, and aims to reduce the risk of bleeding while providing metabolic benefits [2][6] Market Context - Pulmonary hypertension (PH) affects approximately 82 million people globally, with a five-year survival rate of around 50% [2][8] - The global market for PH therapies is projected to reach $18 billion by 2032, with activin signalling inhibitors expected to account for 50% of this market [2] Clinical Benefits - HS235 may offer broad metabolic benefits, including fat-selective weight loss, preservation of lean mass, and improved insulin sensitivity, which are particularly relevant given the high prevalence of obesity and insulin resistance in the PH population [3] Strategic Vision - The acquisition aligns with GSK's strategy to enhance its pipeline with differentiated therapies that address unmet needs in pulmonary hypertension and related chronic diseases [4][10]